Xolid 100mg Suspension - Broad-Spectrum Oxazolidinone Antibacterial Therapy

Product Overview

Xolid 100mg Suspension (100mg per 5ml) is a synthetic, broad-spectrum oxazolidinone antibacterial formulation containing Linezolid. Specially formulated as an oral liquid suspension, Xolid is engineered for pediatric administration and adult patients who have difficulty swallowing solid oral dosage forms. It is indicated for the treatment of severe, complicated Gram-positive bacterial infections, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus faecium (VRE), nosocomial and community-acquired pneumonia, and complicated skin and skin structure infections.

Key Benefits

\n
• \n

  Targeted Activity Against Multi-Drug Resistant Gram-Positives: Highly effective against resistant pathogens, including MRSA, VRE, and penicillin-resistant Streptococcus pneumoniae.

  \n
\n
• \n

  High Oral Bioavailability: Provides near 100% oral bioavailability, allowing seamless transition from intravenous Linezolid therapy to oral outpatient care.

  \n
\n
• \n

  Patient-Friendly Liquid Delivery: Designed for pediatric, elderly, and dysphagic patients requiring precise weight-based dosing.

  \n
\n
• \n

  Unique Mechanism of Action: Minimal risk of cross-resistance with other established antibiotic classes due to its early-stage protein synthesis inhibition.

  \n
\n
• \n

  Effective Tissue Penetration: Rapidly distributes into lung, bone, and soft tissue structures for optimal clinical resolution.

  \n
\n

How It Works

Xolid 100mg Suspension (Linezolid) exerts its bactericidal and bacteriostatic effects by inhibiting bacterial protein synthesis at an earlier stage than most other antibiotics. It selectively binds to the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome. This action prevents the assembly of the functional 70S initiation complex, which is essential for translating messenger RNA (mRNA) into bacterial proteins. By halting protein production early, Xolid inhibits bacterial replication and halts infection progression.

Key Active Ingredients

\n
• \n

  Linezolid (100mg per 5ml reconstituted suspension): Synthetic oxazolidinone antibacterial agent that blocks bacterial 70S ribosomal initiation.

  \n
\n

Directions for Use

\n
1. \n

   Reconstitution (if supplied as dry powder): Tap the bottle to loosen powder. Add the specified volume of cooled, boiled water in two portions, shaking vigorously after each addition until a uniform suspension is formed.

   \n
\n
2. \n

   Administration: Shake the bottle thoroughly before each dose. Measure the exact dose using a calibrated oral dosing syringe or measuring spoon.

   \n
\n
3. \n

   Dosing:

   \n \n
   \n
   • \n

     Pediatric Patients (Infants and Children up to 11 years): Typically 10mg/kg administered orally every 8 hours.

     \n
   \n
   • \n

     Adults and Adolescents (12 years and older): Typically 600mg (30ml) administered orally every 12 hours, or as prescribed by the attending physician.

     \n
   \n
   \n
\n
4. \n

   Food Intake: May be taken with or without food.

   \n
\n

Precautions

\n
• \n

  Prescription-Only Medication: Administer strictly under the supervision and guidance of a licensed medical practitioner.

  \n
\n
• \n

  Monoamine Oxidase (MAO) Inhibition Warning: Linezolid is a reversible, non-selective MAO inhibitor. Avoid concomitant use with serotonergic drugs (SSRIs, SNRIs, tricyclic antidepressants) to prevent serotonin syndrome, and avoid consumption of large amounts of tyramine-rich foods (e.g., aged cheeses, fermented meats, red wine).

  \n
\n
• \n

  Hematologic Monitoring: Reversible myelosuppression (anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported, particularly with courses exceeding 14 days. Complete blood counts (CBC) should be monitored weekly during extended therapy.

  \n
\n
• \n

  Peripheral & Optic Neuropathy: Reported primarily in patients treated for longer than 28 days. Discontinue and evaluate if visual impairment or numbness occurs.

  \n
\n
• \n

  Consult a physician prior to use during pregnancy or lactation.

  \n
\n
• \n

  Keep out of reach of children.

  \n
\n

Storage Instructions

Store dry powder and reconstituted suspension in a cool, dry place below 30°C, protected from direct sunlight and heat. Do not freeze. Keep the bottle tightly closed after each use, and discard any unused reconstituted suspension after 21 days (or as specified on the package label).

Manufacturer Information

Formulated and manufactured in strict compliance with international pharmaceutical quality standards, dedicated to producing advanced anti-infective formulations that effectively combat resistant bacterial pathogens and protect patient health.